KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH

Kezar Life Sciences, Inc.

2025-Q1 EPS reported -$2.27

Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.
Net loss $16.6M ($2.27/share) vs $21.7M ($2.98) in Q1 2024.
PORTOLA Phase 2a: 36% zetomipzomib patients achieved CR with steroid taper vs 0% placebo in relapsed AIH.
R&D expenses fell $5.0M to $12.2M due to PALIZADE trial termination.
Responding to FDA partial clinical hold on PORTOLA; no flares in CR patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.